IQVIA Holdings, Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare clients. Its platform combines proprietary health data, analytics, SaaS tools, and outsourced services to help biopharma companies run trials, understand markets, and commercialize therapies more efficiently.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueData, software, analytics, and information services used to measure markets, track prescribing, and support commercial decisions.
Clinical research and development services that help design, run, and manage trials and related scientific work.
Outsourced commercial operations, field force support, patient engagement, and market access services for life sciences clients.
Medical affairs and scientific strategy services that support product launch and post-approval engagement.
Customers
IQVIA sells primarily to life sciences companies, especially pharmaceutical, biotechnology, device, diagnostic, and consumer health firms. It also serves payers, government and regulatory agencies, providers, distributors, and pharmacies, but the core demand comes from clients that need data, trial execution, and commercialization support across many markets.
Buy clinical research, real-world evidence, analytics, and commercial outsourcing to speed development and launch.
Use market intelligence, consulting, and commercial services to support product adoption and market access.
Purchase data, analytics, and commercial support to improve brand execution and channel performance.
Use healthcare intelligence, evidence, and data services for policy, reimbursement, and oversight decisions.
Buy information services and market data that help with prescribing, distribution, and commercial planning.
Strategy
IQVIA’s strategy is to deepen its Connected Intelligence platform by combining proprietary health data, advanced analytics, SaaS, and domain expertise. It is also expanding the value proposition across both research and commercialization so it can serve clients earlier in development and later in launch and market access, while using its global footprint to win larger multi-country contracts.
Combining proprietary data with analytics and SaaS strengthens differentiation and client stickiness.
Serving clients from trial design through commercialization increases wallet share and reduces dependence on any single service line.
Coverage in over 100 countries helps IQVIA deliver consistent data and services across regulated markets.
Geography
Q1/2026IQVIA operates in over 100 countries, with product-level tracking in 97 markets and sub-national data in more than 70 countries. Management said recent revenue growth in Technology & Analytics Solutions was driven primarily by Europe and Africa, with the Americas also contributing, showing that the business depends on broad international coverage and local regulatory/data access.
Share of the revenue the company reports by geography.
Risks
IQVIA’s business depends on winning and retaining large contracts, executing them profitably, and keeping pace with rapid change in healthcare data and technology. Its leverage, regulatory exposure, and dependence on biopharma R&D and outsourcing trends add financial and operating risk, while clinical trial execution and client budget cycles can affect growth.
- Loss or delay of large contractsImpact: HighLikelihood: Medium
Revenue is tied to multi-year client programs, so timing shifts can materially affect results.
Exposure: Clinical research and commercial outsourcing
- Underpricing and cost overrunsImpact: HighLikelihood: Medium
Fixed-price or complex service contracts can miss margin targets if estimates are wrong or change orders are delayed.
Exposure: Project-based research and consulting work
- Clinical trial execution riskImpact: HighLikelihood: Medium
Failure to recruit investigators or patients can slow studies and hurt client satisfaction and renewals.
Exposure: Research & Development Solutions
- Leverage and covenant constraintsImpact: HighLikelihood: Medium
Senior secured debt and financial covenants can limit acquisitions, capital allocation, and flexibility in downturns.
Exposure: Debt-funded capital structure
- Competitive pressure and technology changeImpact: MediumLikelihood: Medium
The company competes with CROs, consultancies, software vendors, and in-house client capabilities.
Exposure
Accounting
Judgemental itemsClinical and commercial projects may span periods and require judgment on progress and change orders.
Impact: Can shift revenue and margin timing between quarters
The company carries goodwill from acquisitions and tests it annually for impairment.
Impact: A write-down would reduce earnings and equity
Acquisitions require fair value estimates for acquired assets and liabilities.
Impact: Affects amortization expense and reported operating profit
Management disclosed material uncertain tax liabilities and foreign tax complexity.
Impact: Can change tax expense and cash tax payments
The company has significant secured notes and lease obligations.
Impact: Affects interest expense, leverage, and covenant headroom
Similar listed companies
Publicly listed companies with a comparable business focus.
Fortrea Holdings Inc.
FTRE · Services-Medical Laboratories
DaVita Inc
DVA · Services-Misc Health & Allied Services, NEC
DaVita is a kidney-care company built around outpatient dialysis, integrated kidney care management, and related ancillary services.
Workiva Inc
WK · Services-Prepackaged Software
Workiva builds a cloud-based SaaS platform that connects data, workflows, and reporting across finance, sustainability, risk, and audit functions.
Phreesia, Inc.
PHR · Services-Business Services, NEC
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Last updated: 24/09/2026